Cargando…
Skeletal muscle delimited myopathy and verapamil toxicity in SUR2 mutant mouse models of AIMS
ABCC9‐related intellectual disability and myopathy syndrome (AIMS) arises from loss‐of‐function (LoF) mutations in the ABCC9 gene, which encodes the SUR2 subunit of ATP‐sensitive potassium (K(ATP)) channels. K(ATP) channels are found throughout the cardiovascular system and skeletal muscle and coupl...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245035/ https://www.ncbi.nlm.nih.gov/pubmed/37154692 http://dx.doi.org/10.15252/emmm.202216883 |
_version_ | 1785054774818766848 |
---|---|
author | McClenaghan, Conor Mukadam, Maya A Roeglin, Jacob Tryon, Robert C Grabner, Manfred Dayal, Anamika Meyer, Gretchen A Nichols, Colin G |
author_facet | McClenaghan, Conor Mukadam, Maya A Roeglin, Jacob Tryon, Robert C Grabner, Manfred Dayal, Anamika Meyer, Gretchen A Nichols, Colin G |
author_sort | McClenaghan, Conor |
collection | PubMed |
description | ABCC9‐related intellectual disability and myopathy syndrome (AIMS) arises from loss‐of‐function (LoF) mutations in the ABCC9 gene, which encodes the SUR2 subunit of ATP‐sensitive potassium (K(ATP)) channels. K(ATP) channels are found throughout the cardiovascular system and skeletal muscle and couple cellular metabolism to excitability. AIMS individuals show fatigability, muscle spasms, and cardiac dysfunction. We found reduced exercise performance in mouse models of AIMS harboring premature stop codons in ABCC9. Given the roles of K(ATP) channels in all muscles, we sought to determine how myopathy arises using tissue‐selective suppression of K(ATP) and found that LoF in skeletal muscle, specifically, underlies myopathy. In isolated muscle, SUR2 LoF results in abnormal generation of unstimulated forces, potentially explaining painful spasms in AIMS. We sought to determine whether excessive Ca(2+) influx through Ca(V)1.1 channels was responsible for myopathology but found that the Ca(2+) channel blocker verapamil unexpectedly resulted in premature death of AIMS mice and that rendering Ca(V)1.1 channels nonpermeable by mutation failed to reverse pathology; results which caution against the use of calcium channel blockers in AIMS. |
format | Online Article Text |
id | pubmed-10245035 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102450352023-06-08 Skeletal muscle delimited myopathy and verapamil toxicity in SUR2 mutant mouse models of AIMS McClenaghan, Conor Mukadam, Maya A Roeglin, Jacob Tryon, Robert C Grabner, Manfred Dayal, Anamika Meyer, Gretchen A Nichols, Colin G EMBO Mol Med Articles ABCC9‐related intellectual disability and myopathy syndrome (AIMS) arises from loss‐of‐function (LoF) mutations in the ABCC9 gene, which encodes the SUR2 subunit of ATP‐sensitive potassium (K(ATP)) channels. K(ATP) channels are found throughout the cardiovascular system and skeletal muscle and couple cellular metabolism to excitability. AIMS individuals show fatigability, muscle spasms, and cardiac dysfunction. We found reduced exercise performance in mouse models of AIMS harboring premature stop codons in ABCC9. Given the roles of K(ATP) channels in all muscles, we sought to determine how myopathy arises using tissue‐selective suppression of K(ATP) and found that LoF in skeletal muscle, specifically, underlies myopathy. In isolated muscle, SUR2 LoF results in abnormal generation of unstimulated forces, potentially explaining painful spasms in AIMS. We sought to determine whether excessive Ca(2+) influx through Ca(V)1.1 channels was responsible for myopathology but found that the Ca(2+) channel blocker verapamil unexpectedly resulted in premature death of AIMS mice and that rendering Ca(V)1.1 channels nonpermeable by mutation failed to reverse pathology; results which caution against the use of calcium channel blockers in AIMS. John Wiley and Sons Inc. 2023-05-08 /pmc/articles/PMC10245035/ /pubmed/37154692 http://dx.doi.org/10.15252/emmm.202216883 Text en © 2023 The Authors. Published under the terms of the CC BY 4.0 license https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Articles McClenaghan, Conor Mukadam, Maya A Roeglin, Jacob Tryon, Robert C Grabner, Manfred Dayal, Anamika Meyer, Gretchen A Nichols, Colin G Skeletal muscle delimited myopathy and verapamil toxicity in SUR2 mutant mouse models of AIMS |
title | Skeletal muscle delimited myopathy and verapamil toxicity in SUR2 mutant mouse models of AIMS
|
title_full | Skeletal muscle delimited myopathy and verapamil toxicity in SUR2 mutant mouse models of AIMS
|
title_fullStr | Skeletal muscle delimited myopathy and verapamil toxicity in SUR2 mutant mouse models of AIMS
|
title_full_unstemmed | Skeletal muscle delimited myopathy and verapamil toxicity in SUR2 mutant mouse models of AIMS
|
title_short | Skeletal muscle delimited myopathy and verapamil toxicity in SUR2 mutant mouse models of AIMS
|
title_sort | skeletal muscle delimited myopathy and verapamil toxicity in sur2 mutant mouse models of aims |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245035/ https://www.ncbi.nlm.nih.gov/pubmed/37154692 http://dx.doi.org/10.15252/emmm.202216883 |
work_keys_str_mv | AT mcclenaghanconor skeletalmuscledelimitedmyopathyandverapamiltoxicityinsur2mutantmousemodelsofaims AT mukadammayaa skeletalmuscledelimitedmyopathyandverapamiltoxicityinsur2mutantmousemodelsofaims AT roeglinjacob skeletalmuscledelimitedmyopathyandverapamiltoxicityinsur2mutantmousemodelsofaims AT tryonrobertc skeletalmuscledelimitedmyopathyandverapamiltoxicityinsur2mutantmousemodelsofaims AT grabnermanfred skeletalmuscledelimitedmyopathyandverapamiltoxicityinsur2mutantmousemodelsofaims AT dayalanamika skeletalmuscledelimitedmyopathyandverapamiltoxicityinsur2mutantmousemodelsofaims AT meyergretchena skeletalmuscledelimitedmyopathyandverapamiltoxicityinsur2mutantmousemodelsofaims AT nicholscoling skeletalmuscledelimitedmyopathyandverapamiltoxicityinsur2mutantmousemodelsofaims |